Animal Model Market Research Report 2033

Report Description

Animal Model Market Outlook

According to our latest research, the global animal model market size in 2024 stood at USD 2.42 billion, reflecting the sector’s robust expansion, propelled by increasing research activities in drug development and biomedical sciences. The market is set to grow at a CAGR of 6.9% during the forecast period, reaching a projected value of USD 4.75 billion by 2033. This growth is primarily driven by the rising demand for accurate and reliable preclinical models to support pharmaceutical and biotechnology innovation, as well as regulatory requirements for safety and efficacy testing. As per the latest research, the market’s trajectory is underpinned by technological advancements, increased funding for life science research, and the growing prevalence of chronic and infectious diseases worldwide.

One of the most significant growth factors for the animal model market is the surge in drug discovery and development activities globally. Pharmaceutical and biotechnology companies are increasingly relying on animal models to simulate human disease conditions, enabling researchers to evaluate the safety and efficacy of new drug candidates before they reach clinical trials. The rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is also fueling the need for advanced animal models that can closely mimic human pathophysiology. Additionally, regulatory agencies such as the FDA and EMA mandate comprehensive preclinical testing using validated animal models, further solidifying their critical role in the drug development pipeline. The growing complexity of new drug molecules, including biologics and gene therapies, has prompted the adoption of sophisticated animal models, including genetically engineered and humanized models, to ensure translational relevance and predictive accuracy.

Technological advancements represent another pivotal growth catalyst for the animal model market. The integration of cutting-edge gene-editing technologies, such as CRISPR/Cas9, has revolutionized the creation of precise animal models that recapitulate human genetic diseases. These innovations have enabled researchers to generate custom models with specific gene knockouts or knock-ins, accelerating the pace of biomedical research and therapeutic discovery. Furthermore, the development of humanized animal models has bridged the gap between preclinical and clinical research by allowing the study of human-specific biological processes in vivo. The increasing adoption of these advanced technologies by academic institutions, contract research organizations (CROs), and pharmaceutical companies is expected to drive sustained market growth over the next decade.

Another critical driver shaping the animal model market is the growing investment in life sciences research and the expanding scope of toxicology studies. Governments and private organizations are allocating substantial funds to support biomedical research, particularly in genomics, personalized medicine, and infectious disease research. This financial support has led to the establishment of state-of-the-art research facilities and the proliferation of collaborative research initiatives, which, in turn, have amplified the demand for high-quality animal models. The ongoing COVID-19 pandemic has also underscored the importance of animal models in vaccine and therapeutic development, highlighting their indispensable role in addressing emerging global health threats. As research priorities shift towards complex diseases and novel therapeutic modalities, the need for versatile and predictive animal models is anticipated to grow exponentially.

From a regional perspective, North America continues to dominate the animal model market, accounting for the largest revenue share in 2024, followed by Europe and Asia Pacific. The presence of leading pharmaceutical and biotechnology companies, well-established research infrastructure, and favorable regulatory frameworks are key factors contributing to the region’s leadership. Meanwhile, Asia Pacific is emerging as a lucrative market, driven by increasing R&D investments, growing biopharmaceutical industries, and supportive government initiatives aimed at advancing biomedical research. Europe remains a significant player, benefiting from a robust academic research ecosystem and strong collaborations between public and private sectors. Latin America and the Middle East & Africa, while holding smaller market shares, are witnessing gradual growth due to rising awareness and investments in healthcare research.

Get Free Sample Report

Animal Type Analysis

The animal type segment is a cornerstone of the animal model market, encompassing a diverse range of species, each with distinct advantages for specific research applications. Mice continue to be the most widely used animal model, accounting for a substantial portion of the market due to their genetic similarity to humans, rapid breeding cycles, and the availability of well-established genetic modification techniques. Mice models are extensively employed in oncology, immunology, and metabolic research, making them indispensable for both basic and translational studies. Rats, another popular choice, are preferred for their larger size, which facilitates surgical and pharmacological studies, as well as their well-characterized physiology and behavior. The adoption of rats is particularly prominent in neuroscience, cardiovascular, and toxicology research.

Zebrafish have gained significant traction in recent years, especially in developmental biology and genetic research, owing to their transparent embryos and rapid development. The ability to observe organogenesis and disease progression in real-time has positioned zebrafish as a valuable alternative to traditional mammalian models. Guinea pigs and rabbits, while representing a smaller share of the market, play crucial roles in immunology, infectious disease, and ophthalmology studies. Guinea pigs are particularly valuable for respiratory and auditory research, while rabbits are extensively used in antibody production and ocular research. The “Others” category includes species such as pigs, dogs, and non-human primates, which are employed in specialized research areas where higher physiological relevance to humans is required.

The increasing demand for genetically engineered and humanized animal models has further diversified the animal type segment. These models enable researchers to study human-specific genes, proteins, and disease mechanisms in vivo, offering unparalleled insights into complex biological processes. The development of immunodeficient mice and rats, for example, has facilitated the engraftment of human cells and tissues, making them invaluable for oncology and immunotherapy research. As the scope of biomedical research expands, the need for specialized animal models tailored to specific research objectives is expected to drive continued innovation and market growth within this segment.

Regulatory considerations also influence the selection of animal models, as agencies often require specific species for certain types of safety and efficacy testing. The ongoing refinement of animal welfare standards and the adoption of the 3Rs (Replacement, Reduction, and Refinement) principles are prompting researchers to optimize animal model selection and experimental design. This has led to the development of more predictive and ethically sound models, further enhancing the scientific value and translational relevance of animal-based research. Overall, the animal type segment remains a dynamic and evolving component of the animal model market, reflecting the diverse needs of the scientific and medical research communities.

Report Scope

Application Analysis

The application segment of the animal model market is broad and multifaceted, with drug discovery and development representing the largest and most influential category. Animal models are indispensable in the preclinical evaluation of new drug candidates, enabling researchers to assess pharmacokinetics, pharmacodynamics, toxicity, and therapeutic efficacy before advancing to human trials. The growing complexity of drug molecules, including biologics and gene therapies, has heightened the demand for advanced animal models that can accurately predict human responses. As pharmaceutical pipelines expand and regulatory scrutiny intensifies, the reliance on validated and predictive animal models for drug development is expected to remain strong.

Basic research constitutes another significant application area, encompassing studies aimed at understanding fundamental biological processes, disease mechanisms, and gene function. Animal models provide a controlled and reproducible environment for investigating the molecular and cellular underpinnings of health and disease, facilitating the discovery of new therapeutic targets and biomarkers. The integration of genetic engineering and gene-editing technologies has enabled the creation of sophisticated models that recapitulate human diseases at the genetic and phenotypic levels, accelerating the pace of basic and translational research. Academic and research institutions are major contributors to this segment, leveraging animal models to advance scientific knowledge and inform clinical innovation.

Toxicology studies represent a critical application of animal models, as regulatory agencies mandate comprehensive safety assessments of new drugs, chemicals, and consumer products. Animal models are used to evaluate acute and chronic toxicity, carcinogenicity, reproductive toxicity, and other safety endpoints, ensuring that products entering the market meet stringent safety standards. The increasing emphasis on predictive toxicology and the development of alternative testing methods are driving the adoption of more sophisticated and human-relevant animal models. As regulatory frameworks evolve to incorporate emerging scientific insights, the demand for high-quality animal models in toxicology is expected to grow.

Other applications, including vaccine development, infectious disease research, and personalized medicine, are also gaining prominence within the animal model market. The COVID-19 pandemic has underscored the importance of animal models in the rapid development and evaluation of vaccines and therapeutics, highlighting their critical role in addressing public health emergencies. The emergence of novel pathogens and the growing focus on precision medicine are driving the need for animal models that can capture the genetic and phenotypic diversity of human populations. As research priorities shift towards complex and multifactorial diseases, the application segment of the animal model market is poised for continued expansion and diversification.

Technology Analysis

Technological innovation is a driving force behind the evolution of the animal model market, with CRISPR and other gene-editing technologies leading the way. CRISPR/Cas9 has revolutionized the creation of genetically modified animal models, enabling precise and efficient manipulation of specific genes. This technology has accelerated the development of models for a wide range of human diseases, from monogenic disorders to complex polygenic conditions. The ability to generate custom models with targeted gene knockouts or knock-ins has transformed biomedical research, allowing scientists to dissect disease mechanisms and evaluate novel therapeutic strategies with unprecedented accuracy.

Genetic engineering encompasses a broader array of techniques, including transgenesis, gene targeting, and RNA interference, which have enabled the creation of animal models with tailored genetic backgrounds. These models are invaluable for studying gene function, epigenetic regulation, and gene-environment interactions, providing crucial insights into the molecular basis of health and disease. The integration of advanced genetic engineering techniques has also facilitated the development of conditional and inducible models, allowing researchers to control gene expression in a spatially and temporally specific manner. As the demand for sophisticated and physiologically relevant models grows, the adoption of cutting-edge genetic engineering technologies is expected to drive sustained market growth.

Humanized models represent a significant technological advancement in the animal model market, bridging the gap between preclinical and clinical research. These models are engineered to express human genes, proteins, or tissues, enabling the study of human-specific biological processes in vivo. Humanized mice, for example, are widely used in oncology, immunology, and infectious disease research, providing a platform for evaluating the efficacy and safety of novel therapies in a human-relevant context. The development of humanized models has enhanced the predictive value of preclinical studies, reducing the risk of late-stage clinical failures and improving the efficiency of drug development pipelines.

Other emerging technologies, such as advanced imaging, omics platforms, and in vivo phenotyping, are further enhancing the utility and versatility of animal models. The integration of these technologies enables real-time monitoring of disease progression, drug distribution, and therapeutic response, providing a comprehensive understanding of biological systems. The ongoing convergence of genetic engineering, digital imaging, and data analytics is expected to drive the next wave of innovation in the animal model market, enabling the development of more predictive, reproducible, and ethically sound models for biomedical research.

End-User Analysis

The end-user segment of the animal model market is characterized by a diverse array of stakeholders, each with unique requirements and research objectives. Pharmaceutical and biotechnology companies represent the largest end-user group, accounting for a significant share of the market. These organizations rely on animal models for preclinical drug development, safety assessment, and mechanism-of-action studies, leveraging advanced models to accelerate the translation of scientific discoveries into clinical applications. The increasing complexity of drug pipelines, coupled with stringent regulatory requirements, has heightened the demand for predictive and validated animal models within the biopharmaceutical sector.

Academic and research institutes constitute another major end-user segment, driving innovation in basic and translational research. Universities, medical schools, and research centers employ animal models to investigate fundamental biological processes, disease mechanisms, and therapeutic targets. The availability of advanced genetic engineering and gene-editing technologies has empowered academic researchers to develop custom models tailored to specific research questions, fostering scientific discovery and knowledge generation. Collaborative research initiatives and public-private partnerships are further amplifying the role of academic institutions in advancing the animal model market.

Contract research organizations (CROs) play a pivotal role in the animal model market, providing outsourced research services to pharmaceutical, biotechnology, and academic clients. CROs offer expertise in model development, study design, and regulatory compliance, enabling clients to access specialized capabilities and accelerate project timelines. The growing trend towards outsourcing preclinical research, driven by cost considerations and the need for specialized expertise, is fueling the expansion of the CRO segment. CROs are also at the forefront of adopting advanced technologies and best practices, ensuring the delivery of high-quality and reproducible research outcomes.

Other end-users, including government agencies, regulatory bodies, and non-profit organizations, contribute to the animal model market by supporting research and regulatory activities. These stakeholders play a critical role in establishing research standards, funding innovative projects, and promoting the ethical use of animal models. The increasing emphasis on translational research, personalized medicine, and public health preparedness is expected to drive continued engagement and investment from a broad spectrum of end-users, ensuring the sustained growth and diversification of the animal model market.

Opportunities & Threats

The animal model market is poised for significant opportunities over the coming decade, driven by the rapid advancement of gene-editing technologies and the growing focus on personalized medicine. The development of next-generation animal models that closely mimic human genetic and phenotypic diversity presents a unique opportunity to enhance the translational relevance of preclinical research. The integration of omics technologies, such as genomics, proteomics, and metabolomics, with animal models is enabling researchers to gain deeper insights into disease mechanisms and therapeutic responses. This convergence of technologies is expected to drive the development of more predictive and personalized models, accelerating the discovery and validation of novel drug targets and biomarkers.

Another promising opportunity lies in the expansion of the animal model market in emerging economies, particularly in Asia Pacific and Latin America. These regions are witnessing increased investments in biomedical research, the establishment of state-of-the-art research facilities, and the growth of local pharmaceutical and biotechnology industries. Supportive government policies, rising healthcare expenditures, and a growing pool of skilled researchers are creating a conducive environment for market expansion. The increasing adoption of advanced animal models and research technologies in these regions is expected to drive market growth and foster global collaborations in biomedical research.

Despite the numerous growth opportunities, the animal model market faces several restraining factors, chief among them being ethical concerns and stringent regulatory requirements. The use of animals in research is subject to increasing scrutiny from regulatory agencies, animal welfare organizations, and the public. The implementation of the 3Rs principles (Replacement, Reduction, and Refinement) is prompting researchers to explore alternative methods and optimize experimental design. Compliance with evolving animal welfare regulations can increase operational complexity and costs, potentially limiting the adoption of animal models in certain research settings. Balancing scientific advancement with ethical considerations remains a critical challenge for stakeholders in the animal model market.

Regional Outlook

North America remains the largest regional market for animal models, accounting for a market size of USD 1.02 billion in 2024. The region’s dominance is underpinned by the presence of leading pharmaceutical and biotechnology companies, a robust research infrastructure, and favorable regulatory frameworks that support preclinical research. The United States, in particular, is a global leader in animal model research, driven by substantial investments in drug discovery, genomics, and personalized medicine. The region is expected to maintain a strong growth trajectory, supported by ongoing innovation, government funding, and the adoption of advanced research technologies.

Europe is the second-largest regional market, with a market size of USD 0.78 billion in 2024. The region benefits from a well-established academic research ecosystem, strong public-private partnerships, and a commitment to scientific excellence. Regulatory harmonization across the European Union has facilitated cross-border collaborations and the adoption of best practices in animal research. The region is witnessing a steady increase in the adoption of genetically engineered and humanized models, driven by the growing demand for translational research and precision medicine. Europe is projected to grow at a CAGR of 6.2% during the forecast period, reflecting the region’s ongoing commitment to biomedical innovation.

Asia Pacific is emerging as a high-growth market, with a market size of USD 0.44 billion in 2024, fueled by increasing R&D investments, expanding pharmaceutical industries, and supportive government initiatives. China, Japan, and India are at the forefront of this growth, leveraging their large populations, skilled workforce, and growing research capabilities. The region is experiencing a surge in demand for advanced animal models and research services, driven by the rising prevalence of chronic diseases and the need for innovative therapeutic solutions. Latin America and the Middle East & Africa, while representing smaller market shares, are witnessing gradual growth due to rising awareness, healthcare investments, and the expansion of local research infrastructure. Collectively, these regional trends underscore the global nature of the animal model market and the diverse factors driving its evolution.

Get Free Sample Report

Competitor Outlook

The animal model market is characterized by a highly competitive landscape, with a mix of established players and emerging companies vying for market share through innovation, strategic collaborations, and expansion into new geographic markets. Leading companies are investing heavily in research and development to create advanced animal models, enhance genetic engineering capabilities, and improve the predictive value of preclinical studies. The competitive environment is further intensified by the growing demand for specialized models, the integration of cutting-edge technologies, and the need to comply with evolving regulatory requirements. Companies are also focusing on expanding their service offerings, including custom model development, phenotyping, and in vivo imaging, to cater to the diverse needs of pharmaceutical, biotechnology, and academic clients.

Strategic partnerships and collaborations are a hallmark of the competitive landscape, enabling companies to leverage complementary strengths, access new technologies, and accelerate product development. Mergers and acquisitions are also common, as companies seek to enhance their portfolios, expand their geographic reach, and gain access to new customer segments. The rise of contract research organizations (CROs) has added another layer of competition, as these entities provide specialized research services and expertise, enabling clients to outsource complex and resource-intensive projects. The ability to deliver high-quality, reproducible, and ethically sound research outcomes is a key differentiator in the market, driving companies to invest in quality assurance, regulatory compliance, and staff training.

The competitive landscape is further shaped by the increasing emphasis on ethical considerations and animal welfare. Companies are adopting best practices in animal care, implementing the 3Rs principles, and investing in alternative methods to minimize animal use and enhance scientific validity. The development of humanized and genetically engineered models is a focal point for innovation, as these models offer greater translational relevance and predictive accuracy. Companies are also leveraging digital technologies, such as advanced imaging and data analytics, to enhance model characterization and study design, further differentiating their offerings in the market.

Major players in the animal model market include Charles River Laboratories, The Jackson Laboratory, Taconic Biosciences, Envigo (now part of Inotiv), and Janvier Labs, among others. Charles River Laboratories is a global leader in the provision of animal models and related research services, offering a comprehensive portfolio of genetically engineered models, humanized models, and preclinical testing services. The Jackson Laboratory is renowned for its expertise in mouse genetics and the development of disease-specific models, supporting a wide range of research applications. Taconic Biosciences specializes in the creation of custom and off-the-shelf animal models, with a focus on genetically engineered and humanized models. Envigo, now part of Inotiv, provides a broad range of research models and services, including toxicology, pharmacology, and safety assessment.

Janvier Labs is a leading European provider of animal models, with a strong emphasis on quality, animal welfare, and customer support. These companies, along with a host of regional and niche players, are driving innovation and setting industry standards in the animal model market. The competitive landscape is expected to remain dynamic, with ongoing investments in technology, infrastructure, and strategic partnerships shaping the future of the market. As the demand for advanced and predictive animal models continues to grow, companies that can deliver high-quality, ethically sound, and scientifically relevant solutions will be well-positioned to capitalize on emerging opportunities and drive sustained market growth.

Key Players

• Charles River Laboratories International, Inc.
• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Envigo (now part of Inotiv, Inc.)
• Janvier Labs
• GenOway S.A.
• Harlan Laboratories (now part of Envigo/Inotiv)
• Crown Bioscience Inc.
• Transgenic, Inc.
• SAGE Labs, Inc. (now part of Horizon Discovery Group plc)
• Laboratory Corporation of America Holdings (LabCorp)
• Ozgene Pty Ltd.
• Shanghai SLAC Laboratory Animal Co., Ltd.
• Syngene International Limited
• Harvard Bioscience, Inc.
• Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
• Biomedical Research Models, Inc.
• Pharmaron, Inc.
• GemPharmatech Co., Ltd.
• Vivo Bio Tech Ltd.

Get Free Sample Report